Pulse Biosciences,, On December 18, 2024, The Co's Co-Chairman And Majority Shareholder, Robert W. Duggan, Exercised All Of The Warrants He Acquired In The Co's 2024 Rights Offering, Corresponding To $58.4M Totaling To 5,306,156 Shares Of Company...
Pulse Biosciences,, On December 18, 2024, The Co's Co-Chairman And Majority Shareholder, Robert W. Duggan, Exercised All Of The Warrants He Acquired In The Co's 2024 Rights Offering, Corresponding To $58.4M Totaling To 5,306,156 Shares Of Company...
Pulse Biosciences,, On December 18, 2024, The Co's Co-Chairman And Majority Shareholder, Robert W. Duggan, Exercised All Of The Warrants He Acquired In The Co's 2024 Rights Offering, Corresponding To $58.4M Totaling To 5,306,156 Shares Of Company Common Stock
Pulse Biosciences，，2024年12月18日，該公司聯席董事長兼大股東羅伯特·杜根行使了他在公司2024年供股中獲得的所有認股權證，相當於5,840萬美元，共計5,306,156股公司普通股
Pulse Biosciences, Inc. (NASDAQ:PLSE) (the "Company" or "Pulse Biosciences"), a novel bioelectric medicine company commercializing the CellFX System powered by Nano-Pulse Stimulation (NPS) technology, today announced that, on December 18, 2024, the Company's Co-Chairman and majority shareholder, Robert W. Duggan, exercised all of the warrants he acquired in the Company's 2024 rights offering, corresponding to $58.4 million totaling to 5,306,156 shares of Company common stock. Mr. Duggan also confirmed that, from December 11, 2024 through this past Friday, December 13, 2024, he has purchased an additional 156,714 shares of Pulse Biosciences. These transactions bring Mr. Duggan's current ownership in the Company to approximately 70%.
Pulse Biosciences, Inc.（納斯達克股票代碼：PLSE）（「公司」 或 「Pulse Biosciences」）是一家將由納米脈衝刺激（NPS）技術提供支持的CellFX系統商業化的新型生物電醫學公司。該公司聯席董事長兼大股東羅伯特·杜根於2024年12月18日行使了他在公司2024年供股中獲得的所有認股權證，相當於58.4美元百萬股公司普通股總額爲5,306,156股。杜根還證實，從2024年12月11日到上週五，即2024年12月13日，他又購買了Pulse Biosciences的156,714股股票。這些交易使杜根先生目前在公司的所有權達到約70％。
